Table 1.
Immune Checkpoint |
microRNA | Cancer | Reference |
---|---|---|---|
PD-1 | miR-374b, miR-4717 | Liver cancer | [64,65] |
PD-1/PD-L1 | miR-183 | RCC | [66] |
miR-138-5p, miR-200b, miR-429, miR-508 | Lung cancer | [67,68] | |
PD-L1 | miR-142-5p | PC, OC | [69,70] |
miR-497-5p | ccRCC | [71] | |
miR-20-b, miR-21, miR-130b, miR-138-5p, miR-148a-3p, miR-191-5p | CRC | [11,72,73,74] | |
miR-195, miR-424-5p, miR-497, miR-873, miR-3609 | BC | [75,76,77,78] | |
miR-17-5p, miR-146a | Melanoma | [79,80] | |
miR-15a, miR-15b, miR-16, miR-193a-3p, miR-320a | Pleural Mesothelioma | [81,82] | |
miR-155, miR-195, miR-214 | B-cell lymphoma | [83,84,85] | |
miR-16, miR-195 | Prostate cancer | [86] | |
miR-34a, miR-34b, miR-34c, miR-140, miR-200, miR-200a-3p, miR-3127-5p | Lung cancer | [87,88,89,90,91] | |
miR-34a | AML | [92] | |
miR-23a-3p, miR-570 | Liver cancer | [93,94] | |
miR-375 | HNSCC | [95] | |
miR-145 | OC, bladder cancer | [96,97] | |
miR-513a-5p | Retinoblastoma | [98] | |
miR-105-5p, miR-152, miR-200b, miR-200c, miR-570 | GC | [99,100,101,102,103] | |
miR-18a, miR-140, miR-142, miR-340, miR-383 | Cervical cancer | [104] | |
miR-217 | Laryngeal cancer | [105] | |
miR-20b-5p | Models of lung and BC | [106] | |
miR-194-5p | PC | [107] | |
PD-L1+B7-H3 | miR-326 | Lung cancer | [8] |
PD-1, CTLA-4 | miR-424 | OC | [108] |
miR-138-5p | Glioma | [109] | |
CD80/CTLA-4 | miR-424 | CRC | [110] |
PD-1, PD-L1, CTLA-4 | miR-33a | Lung cancer | [111] |
PD-1, BTLA, Tim-3 | miR-28 | Melanoma mouse model | [112] |
BTLA | miR-32 | OC | [113] |
Tim-3 | miR-498 | AML | [114] |
IDO1 | miR-153, miR-448 | CRC | [115,116] |
Gal-3 | miR-424-3p | OC | [117] |
miR-128 | CRC | [118] | |
Gal-9 | miR-22 | Liver cancer | [119] |
miR-15b-5p, miR-455-5p, miR-1237, miR-1246 | CRC | [120,121] | |
ICOS (B7-H2)/ICOSL | miR-24 | GC | [122] |
B7-H3 | miR-29 (a, b and c) | Neuroblastoma, sarcoma, brain tumors | [123] |
miR-145 | Lung cancer | [124] | |
miR-28-5p, miR-29a, miR-128, miR-145, miR-155/miR-143, miR-187, miR-192, miR-335-5p, miR-378, miR-1301-3p | CRC | [125,126,127,128,129] | |
miR-187 | ccRCC | [130] | |
miR-29c | Melanoma, CRC |
[131,132] | |
miR-29c, miR-34b, miR-124a, miR-125b-2, miR-214, miR-297, miR-326, miR-363, miR-380-5p, miR-506, miR-555, miR-567, miR-593, miR-601, miR-665, miR-708, miR-885-3p, miR-940 | BC | [133] | |
miR-539 | Glioma | [134] | |
miR-124 | Osteosarcoma | [135] | |
miR-506 | Mantle cell lymphoma | [136] | |
miR-214 | Multiple myeloma | [137] | |
miR-29, miR-1253 | Medulloblastoma | [138,139] | |
miR-199a | Cervical cancer | [140] | |
B7-H5 (VISTA, BTNL2) | miR-125a-5p | GC | [141] |
B7-H4 (VTCN1) | miR-155/miR-143, miR-1207 | CRC | [126,142] |
miR-7–5p, hsa-let-7c, hsa-let-7f-5p, miR-17–3p, miR-21–3p, miR-21–5p, miR-24–1-5p, miR-27b-3p, miR-31–3p, miR-31–5p, miR-33a-5p, miR-33b-5p, miR-122–3p, miR-130b-3p, miR-138–1-3p, miR-148a-3p, miR-149–3p, miR-183–3p, miR-186–5p, miR-196a-5p, hsa-miR-204–3p, miR-299–5p, miR-302a-3p, miR-302e, miR-335–3p, miR-335–5p, miR-361–5p, miR-374c-5p, miR-483–3p, miR-513a-5p, miR-519e-3p, miR-520d-5p, miR-525–5p, miR-615–3p, miR-642a-5p, miR-744–5p, miR-937, miR-1246, miRPlus-G1246–3p, miR-1260a, miR-1265, miR-1284, miR-1290, miR-1973, miR-2115–3p, miR-2116–5p, miR-3178, miR-3202, miR-3646, miR-3651, miR-3676–3p, miR-3685, miR-3686, miR-4258, miR-4279, miR-4284, miR-4288, miR-4290, miR-4306, miR-4324 | PC | [143] | |
B7-H6 (NCR3LG1) | miR-93, miR-195, miR-340 | BC | [76] |
B7-H7 (HHLA2) | miR-3116, miR-6870-5p | ccRCC | [144] |
Footnotes: RCC—renal cell cancer; PC—pancreatic cancer; OC—ovarian cancer; CRC—colorectal cancer; BC—breast cancer; AML—acute myeloid leukemia; HNSCC—head and neck squamous cell cancer; GC—gastric cancer.